Comparative Pharmacology
Head-to-head clinical analysis: VANSIL versus VERMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANSIL versus VERMIDOL.
VANSIL vs VERMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vansil (oxamniquine) is an antischistosomal agent that increases calcium permeability in susceptible schistosomes, leading to muscle contraction, paralysis, and eventual death of the parasite. It is specifically active against Schistosoma mansoni.
VERMIDOL is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis and attenuating pain, inflammation, and fever.
20 mg/kg orally twice daily for 1 day (maximum single dose: 1 g).
200 mg orally twice daily for 3 days; maximum 400 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 85-105 hours in patients with normal renal function, allowing once-daily dosing; prolonged in renal impairment
Terminal elimination half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h) and elderly.
Primarily renal (70-80% as unchanged drug) with minor biliary/fecal elimination (15-20%) and hepatic metabolism (10-15%)
Renal: ~60-70% as unchanged drug; biliary/fecal: ~20-30%; minor metabolism via hepatic CYP3A4.
Category C
Category C
Anthelmintic
Anthelmintic